CVM Cel Sci Corp

Price (delayed)

$18.89

Market cap

$765.6M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.88

Enterprise value

$755.76M

Sector: Healthcare
Industry: Biotechnology

CEL-SCI believes that boosting a patient’s immune system while it is still intact should provide the greatest possible impact on survival. Therefore, in the Phase 3 study CEL-SCI treated patients ...

Highlights

The equity has increased by 46% from the previous quarter
CVM's debt is down by 3.9% year-on-year
Cel Sci's quick ratio has increased by 32% YoY but it has decreased by 20% from the previous quarter
The gross profit has increased by 22% YoY but it has decreased by 9% from the previous quarter
CVM's net income is down by 14% year-on-year and by 9% since the previous quarter

Key stats

What are the main financial stats of CVM
Market
Shares outstanding
40.53M
Market cap
$765.6M
Enterprise value
$755.76M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
26.04
Price to sales (P/S)
1,344.1
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,390.61
Earnings
Revenue
$543,473
EBIT
-$31.89M
EBITDA
-$29.51M
Free cash flow
-$20.71M
Per share
EPS
-$0.88
Free cash flow per share
-$0.54
Book value per share
$0.73
Revenue per share
$0.01
TBVPS
$1.28
Balance sheet
Total assets
$49.61M
Total liabilities
$20.78M
Debt
$13.69M
Equity
$28.84M
Working capital
$16.36M
Liquidity
Debt to equity
0.47
Current ratio
3.23
Quick ratio
3.22
Net debt/EBITDA
0.33
Margins
EBITDA margin
-5,429.7%
Gross margin
100%
Net margin
-6,060.4%
Operating margin
-5,705.5%
Efficiency
Return on assets
-77.2%
Return on equity
-157.6%
Return on invested capital
-101.8%
Return on capital employed
-75.4%
Return on sales
-5,867%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CVM stock price

How has the Cel Sci stock price performed over time
Intraday
-15.41%
1 week
-8.61%
1 month
8.13%
1 year
20.32%
YTD
62.01%
QTD
24.19%

Financial performance

How have Cel Sci's revenue and profit performed over time
Revenue
$543,473
Gross profit
$543,473
Operating income
-$31.01M
Net income
-$32.94M
Gross margin
100%
Net margin
-6,060.4%
Cel Sci's operating income has decreased by 41% YoY and by 7% from the previous quarter
The gross profit has increased by 22% YoY but it has decreased by 9% from the previous quarter
The company's revenue rose by 22% YoY but it fell by 9% QoQ
CVM's net margin is down by 20% since the previous quarter but it is up by 7% year-on-year

Growth

What is Cel Sci's growth rate over time

Valuation

What is Cel Sci stock price valuation
P/E
N/A
P/B
26.04
P/S
1,344.1
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,390.61
The company's EPS fell by 7% QoQ but it rose by 3.3% YoY
The equity has increased by 46% from the previous quarter
The stock's price to book (P/B) is 7% more than its last 4 quarters average of 24.4
CVM's P/S is 70% above its last 4 quarters average of 789.7
The company's revenue rose by 22% YoY but it fell by 9% QoQ

Efficiency

How efficient is Cel Sci business performance
CVM's return on equity has surged by 78% year-on-year and by 17% since the previous quarter
The return on assets has grown by 25% year-on-year and by 2.8% since the previous quarter
The company's return on sales fell by 20% QoQ but it rose by 4.3% YoY
Cel Sci's return on invested capital has decreased by 7% QoQ

Dividends

What is CVM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CVM.

Financial health

How did Cel Sci financials performed over time
The total assets is 139% more than the total liabilities
The total assets has soared by 58% YoY and by 22% from the previous quarter
Cel Sci's current ratio has increased by 37% YoY but it has decreased by 22% from the previous quarter
CVM's debt is 53% smaller than its equity
The company's debt to equity has shrunk by 70% YoY and by 34% QoQ
The equity has increased by 46% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.